Combined MEK and Bcl-2/XL inhibition is effective in high-grade serous ovarian cancer patient–derived xenograft models and BIM levels are predictive of responsiveness

Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Combined MEK and Bcl-2/XL inhibition is effective in high-grade serous ovarian cancer patient–derived xenograft models and BIM levels are predictive of responsiveness'. Together they form a unique fingerprint.

Medicine & Life Sciences